Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer-Reference-Cited by-同舟云学术

Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer

Published:2021-05-26 Issue:5 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Hoon Siao-Nge¹²,Lau Peter K H²³,White Alison M⁴⁵,Bulsara Max K⁶⁷⁸,Banks Patricia D³⁹,Redfern Andrew D¹⁰¹¹

Affiliation:

1. Medical Oncology Department; St John of God Midland; Perth Australia

2. Medical Oncology Department; Sir Charles Gairdner Hospital; Perth Australia

3. Medical Oncology Department; Peter MacCallum Cancer Centre; Melbourne Australia

4. Murdoch Community Hospice; St John of God Hospital Murdoch; Perth Australia

5. Palliative Care Department; Royal Perth Hospital; Perth Australia

6. Institute for Health Research; University of Notre Dame Australia; Fremantle Australia

7. School of Population and Global Health; The University of Western Australia; Perth Australia

8. Division of Surgery and Interventional Science; University College London; London UK

9. Medical Oncology Department; University Hospital Geelong; Geelong Australia

10. School of Medicine; University of Western Australia; Perth Australia

11. Medical Oncology Department; Fiona Stanley Hospital; Perth Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Reference417 articles.

1. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy;Foedermayr;Cancer Research,2013

2. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer;Steger;Cancer Research,2009

3. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24);Steger;European Journal of Cancer Supplement,2009

4. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC);Steger;European Journal of Cancer Supplement,2010

5. Steger GG Greil R Jakesz R Lang A Mlineritsch B Rudas M Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC) Journal of Clinical Oncology 2010 Abstract no. 530

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capecitabine monotherapy as first-line treatment in advanced HER2-normal breast cancer – a nationwide, retrospective study;Acta Oncologica;2024-06-23

2. Clinical effectiveness and safety of gemcitabine plus capecitabine in the treatment of advanced triple-negative breast cancer;American Journal of Translational Research;2024

3. Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma;The Oncologist;2023-12-09

4. Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate – The ICE randomized clinical trial;European Journal of Cancer;2023-11

5. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer;Current Oncology;2023-06-24